ISRCTN49135540 https://doi.org/10.1186/ISRCTN49135540

Phase I trial code: PKM17308

Submission date 15/11/2023	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 17/11/2023	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 17/11/2023	**Condition category** Other	[_] Individual participant data [_] Record updated in last year

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Dr Litza Marie McKenzie

Contact details
Mere Way, Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)115 974 9000
litza.mckenzie@quotientsciences.com

Type(s)
Public, Scientific

Contact name
Dr Study Director Clinical Sciences & Operations Sanofi

Contact details
1 Avenue Pierre Brossolette
Chilly-Mazarin
France
91380
None provided
uk-medicalinformation@sanofi.com

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Integrated Research Application System (IRAS)
1005387

Protocol serial number
IRAS 1005387

Study information

Scientific Title
Phase I trial code: PKM17308

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
approved 10/06/2022, North West - Greater Manchester Central Research Ethics Committee (3rd Floor Barlow House 4 Minshull Street, Manchester, LM1 3DZ, United Kingdom; +44 (0)207 104 8244, (0)207 104 8004; gmcentral.rec@hra.nhs.uk), ref: 22/NW/0258

Study design
Pharmacokinetics (PK) study in 12 healthy participants

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s))
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
15/06/2023

Eligibility

Key inclusion criteria
Healthy human volunteer

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Upper age limit
65 years

Sex
All

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

24/04/2023

Date of final enrolment
15/06/2023

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences - Nottingham
Mere Way, Ruddington
Nottingham
United Kingdom
NG11 6JS

Sponsor information

Organisation
Sanofi-Aventis Recherche & Développement

Funder(s)

Funder type
Industry

Funder Name
Sanofi-Aventis Recherche & Développement

Results and Publications

Individual participant data (IPD) sharing plan
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and

study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

IPD sharing plan summary

Not expected to be made available